Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term
Abstract Seizures in patients with developmental and epileptic encephalopathies (DEEs) are often highly resistant to various antiseizure medications. Perampanel (PER) is a novel antiseizure medication that non-competitively inhibits the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor a...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-82014-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850136849450795008 |
|---|---|
| author | Hirokazu Yamagishi Hitoshi Osaka Kazuhiro Muramatsu Karin Kojima Yukifumi Monden Tadahiro Mitani Yuta Asakura Keizo Wakae Kohei Nagai Toshihiro Tajima |
| author_facet | Hirokazu Yamagishi Hitoshi Osaka Kazuhiro Muramatsu Karin Kojima Yukifumi Monden Tadahiro Mitani Yuta Asakura Keizo Wakae Kohei Nagai Toshihiro Tajima |
| author_sort | Hirokazu Yamagishi |
| collection | DOAJ |
| description | Abstract Seizures in patients with developmental and epileptic encephalopathies (DEEs) are often highly resistant to various antiseizure medications. Perampanel (PER) is a novel antiseizure medication that non-competitively inhibits the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor and is expected to reduce seizure frequency not only for focal seizures and generalized tonic-clonic seizures (GTCS) but also for other seizure types. This study aimed to clarify the long-term therapeutic efficacy and tolerability of PER in patients with DEEs. We analyzed data regarding patients’ background characteristics, medication retention, trends in seizure frequency, and adverse events obtained from 24 patients with DEEs who had been on PER treatment for 60 months. The retention rates were 62.5% and 46.9% at 12 and 60 months, respectively. At 60 months after PER initiation, the rate of patients with > 50% seizure reduction was 33.3%, 33.3%, 38.5%, 54.5%, 54.5%, and 36.4% among patients with atypical absence seizures, tonic seizures, focal seizures, GTCS, myoclonic seizures, and atonic seizures, respectively. The frequency of adverse events was 70.8%. PER showed long-term efficacy in various seizure types. PER is a promising treatment option for patients with DEEs. |
| format | Article |
| id | doaj-art-e9fd2f8406004e5a9074568569ab70c3 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-e9fd2f8406004e5a9074568569ab70c32025-08-20T02:31:00ZengNature PortfolioScientific Reports2045-23222024-12-011411910.1038/s41598-024-82014-5Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long termHirokazu Yamagishi0Hitoshi Osaka1Kazuhiro Muramatsu2Karin Kojima3Yukifumi Monden4Tadahiro Mitani5Yuta Asakura6Keizo Wakae7Kohei Nagai8Toshihiro Tajima9Department of Pediatrics, Jichi Medical UniversityDepartment of Pediatrics, Jichi Medical UniversityDepartment of Pediatrics, Jichi Medical UniversityDepartment of Pediatrics, Jichi Medical UniversityDepartment of Pediatrics, Jichi Medical UniversityDepartment of Pediatrics, Jichi Medical UniversityDepartment of Pediatrics, Jichi Medical UniversityDepartment of Pediatrics, Jichi Medical UniversityDepartment of Pediatrics, Jichi Medical UniversityDepartment of Pediatrics, Jichi Medical UniversityAbstract Seizures in patients with developmental and epileptic encephalopathies (DEEs) are often highly resistant to various antiseizure medications. Perampanel (PER) is a novel antiseizure medication that non-competitively inhibits the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor and is expected to reduce seizure frequency not only for focal seizures and generalized tonic-clonic seizures (GTCS) but also for other seizure types. This study aimed to clarify the long-term therapeutic efficacy and tolerability of PER in patients with DEEs. We analyzed data regarding patients’ background characteristics, medication retention, trends in seizure frequency, and adverse events obtained from 24 patients with DEEs who had been on PER treatment for 60 months. The retention rates were 62.5% and 46.9% at 12 and 60 months, respectively. At 60 months after PER initiation, the rate of patients with > 50% seizure reduction was 33.3%, 33.3%, 38.5%, 54.5%, 54.5%, and 36.4% among patients with atypical absence seizures, tonic seizures, focal seizures, GTCS, myoclonic seizures, and atonic seizures, respectively. The frequency of adverse events was 70.8%. PER showed long-term efficacy in various seizure types. PER is a promising treatment option for patients with DEEs.https://doi.org/10.1038/s41598-024-82014-5PerampanelLennox-Gastaut syndromeEpilepsy with myoclonic atonic seizuresLong-termEfficacy & safety |
| spellingShingle | Hirokazu Yamagishi Hitoshi Osaka Kazuhiro Muramatsu Karin Kojima Yukifumi Monden Tadahiro Mitani Yuta Asakura Keizo Wakae Kohei Nagai Toshihiro Tajima Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term Scientific Reports Perampanel Lennox-Gastaut syndrome Epilepsy with myoclonic atonic seizures Long-term Efficacy & safety |
| title | Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term |
| title_full | Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term |
| title_fullStr | Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term |
| title_full_unstemmed | Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term |
| title_short | Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term |
| title_sort | perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term |
| topic | Perampanel Lennox-Gastaut syndrome Epilepsy with myoclonic atonic seizures Long-term Efficacy & safety |
| url | https://doi.org/10.1038/s41598-024-82014-5 |
| work_keys_str_mv | AT hirokazuyamagishi perampanelreducesseizurefrequencyinpatientswithdevelopmentalandepilepticencephalopathyforalongterm AT hitoshiosaka perampanelreducesseizurefrequencyinpatientswithdevelopmentalandepilepticencephalopathyforalongterm AT kazuhiromuramatsu perampanelreducesseizurefrequencyinpatientswithdevelopmentalandepilepticencephalopathyforalongterm AT karinkojima perampanelreducesseizurefrequencyinpatientswithdevelopmentalandepilepticencephalopathyforalongterm AT yukifumimonden perampanelreducesseizurefrequencyinpatientswithdevelopmentalandepilepticencephalopathyforalongterm AT tadahiromitani perampanelreducesseizurefrequencyinpatientswithdevelopmentalandepilepticencephalopathyforalongterm AT yutaasakura perampanelreducesseizurefrequencyinpatientswithdevelopmentalandepilepticencephalopathyforalongterm AT keizowakae perampanelreducesseizurefrequencyinpatientswithdevelopmentalandepilepticencephalopathyforalongterm AT koheinagai perampanelreducesseizurefrequencyinpatientswithdevelopmentalandepilepticencephalopathyforalongterm AT toshihirotajima perampanelreducesseizurefrequencyinpatientswithdevelopmentalandepilepticencephalopathyforalongterm |